Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Regulation Canada

Health Canada Clarifies Position On Biosimilar Switching

  • News

Executive Summary

As part of its update to a fact sheet on biologics and biosimilars, Health Canada has clarified its position on biosimilar switching.

You may also be interested in...



Canada Maintains Momentum With Another Biosimilar Switching Scheme

As momentum continues for biosimilar switching programs in Canada, Yukon has become the latest jurisdiction to announce such an initiative.

Ontario Welcomes Biosimilar Switching Policy Following Extended Campaign

Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.

Saskatchewan Switching Scheme Boosts Biosimilars In Canada

Saskatchewan has become the latest Canadian province to introduce a biosimilar switching scheme, adding further momentum to the roll-out of similar initiatives across Canada.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin
Generics Bulletin

Topics

Tags:
Biosimilars Regulation Canada
Latest Headlines

Hybrid Specialist Azurity Snaps Up Complex Generics Firm Slayback Pharma

Shortlist Revealed Ahead Of October Awards

Teva Looks To Novartis To Replace Departing Dethlefs

US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla

See All
UsernamePublicRestriction

Register

GB149131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By